BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-3023…
| Periodo | 2026-11 | 2026-09 |
|---|---|---|
| Real | — | $-8.75 |
| Estimado | $-0.90 | $-0.77 |
| Sorpresa | — | -1036.4% |
| Métrica | BLSM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
BlossomHill Therapeutics, Inc. cotiza a 13.94 USD y tiene una capitalización bursátil de $443M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud